Get the Stockscreener App
0.5195
8.70%
-0.0495
Valion Bio Inc stock is traded at $0.5195, with a volume of 97,059.
It is down -8.70% in the last 24 hours and down -39.57% over the past month.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
See More
Previous Close:
$0.569
Open:
$0.5689
24h Volume:
97,059
Relative Volume:
0.49
Market Cap:
$1.66M
Revenue:
$232.00K
Net Income/Loss:
$-12.13M
P/E Ratio:
-0.0581
EPS:
-8.9454
Net Cash Flow:
$-10.29M
1W Performance:
-13.39%
1M Performance:
-39.57%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.5195
$0.5689
1-Week Range:
$0.5109
$0.605
52-Week Range:
$0.5109
$1.1996
Valion Bio Inc Stock (VBIO) Company Profile
Name
Valion Bio Inc
Sector
Industry
Phone
(888)276-6888
Address
1305 E. HOUSTON STREET, SAN ANTONIO
Compare VBIO vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.00 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.38 | 3.16B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.54 | 425.01M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.26 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.909 | 269.09M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
46.61 | 0 | 0 | 0 | 0 | 0.00 |
Valion Bio Inc Stock (VBIO) Latest News
Valion Bio (VBIO) CFO exercises 92 RSUs, holds 618 common shares after conversion - Stock Titan
Valion Bio Completes New Preferred Stock Financing Round - TipRanks
Valion Bio issues preferred shares and warrants in $250,000 private placement - Investing.com UK
Valion Bio (NASDAQ: VBIO) adds $250,000 via Series B preferred share and warrant sale - Stock Titan
VBIO Price Today: Valion Bio, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Valion Bio's Initiative for Radiation Protection Solutions - GuruFocus
House committee directs Pentagon plan for radiation drugs By Investing.com - Investing.com Australia
House committee directs Pentagon plan for radiation drugs - Investing.com UK
Congress presses for radiation drugs that work before and after exposure - Stock Titan
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures - Sahm
Valion Bio (NASDAQ: VBIO) investors approve major equity plan boost and share issuances - Stock Titan
Valion Bio (VBIO) Stock Analysis Report | Financials & Insights - Benzinga
VBIO News | VALION BIO INC (NASDAQ:VBIO) - ChartMill
VBIO Stock Price, Quote & Chart | VALION BIO INC (NASDAQ:VBIO) - ChartMill
VBIO SEC FilingsValion Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Valion Bio (VBIO) CEO converts 2,206 RSUs, now holds 11,030 shares - Stock Titan
Quest Diagnostics Declares Quarterly Cash Dividend - Weekly Voice
Valion radiation drug, oral option in joint US defense, BARDA briefing - Stock Titan
VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME - PR Newswire
Valion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling work - MSN
Valion Bio subsidiary secures exclusive NMR platform license By Investing.com - Investing.com Australia
Valion Bio (VBIO) Reports Financial Position and Strategic Focus for 2026 - GuruFocus
Valion Bio's Velocity Bioworks Secures Exclusive Commercial Lice - GuruFocus
VBIO Technical Analysis & Stock Price Forecast - Intellectia AI
VBIO PE Ratio & Valuation, Is VBIO Overvalued - Intellectia AI
VBIO Should I Buy - Intellectia AI
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS - GuruFocus
Valion Bio Reports Q1 2026 Earnings and Strategic Outlook - Intellectia AI
Valion Bio Reports Q1 Results, Advances Entolimod Platform - TipRanks
Valion Bio, Inc. Common Stock Q1 2026 Earnings Call Transcript - MarketBeat
Valion Bio, Inc. 1Q 2026: Revenue $24K, Net loss $(6.20M), EPS $(2.23) — 10-Q Summary - TradingView
Valion Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Valion Bio, Inc. Quarterly Earnings Report - Stock Titan
VBIO: Velocity Bioworks launch and federally funded entolimod development drive 2026 growth outlook - TradingView
Valion Bio subsidiary secures exclusive NMR platform license - Investing.com
Transcript : Valion Bio, Inc., Q1 2026 Earnings Call, May 14, 2026 - marketscreener.com
Valion Bio Q1 2026 Earnings Call: Complete Transcript - Benzinga
Valion Bio reports first quarter 2026 financial results - marketscreener.com
Valion Bio Reports First Quarter 2026 Financial Results - TradingView
Valion Bio (VBIO) widens Q1 2026 loss as it builds TLR5 and CDMO platform - Stock Titan
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform - PR Newswire
Valion Bio Inc (VBIO) Earnings Calendar_Earnings Forecast_Financial Report and Earnings Call - Tiger Brokers
Valion Bio (VBIO.US) will release its earnings report after the market closes on May 14. - Moomoo
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026 - Morningstar
VBIO Stock Chart | VALION BIO INC (NASDAQ:VBIO) - ChartMill
3i group (TIVC) files amendment showing 9.99% holding and convertible exposure - Stock Titan
Number of shareholders of Valion Bio, Inc. – NASDAQ:VBIO - TradingView
Valion Bio Inc Stock (VBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):